
Please try another search
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Jake Simson | 38 | 2023 | Non Executive Independent Director |
Scott Robertson | - | 2023 | Independent Director |
Michael F. Powell | 69 | 2024 | Independent Chairman of the Board |
Nils Lonberg | 68 | 2019 | Non-Executive Independent Director |
Kiran Mazumdar-Shaw | 71 | 2018 | Independent Director |
Ryan Cohlhepp | 48 | 2020 | President, COO & Director |
Claire Mazumdar Clemon | 35 | 2020 | CEO & Director |
Jonathan Edwards | 39 | - | Board Observer |
Ketan Patel | 49 | 2023 | Board Observer |
Anders D. Hove | 58 | - | Board Observer |
Carolyn Ng | 40 | 2023 | Non-Executive Independent Director |
Kathryn Haviland | 48 | 2023 | Independent Director |
Christopher J. Bowden | 64 | 2024 | Independent Director |
Jason Fuller | 47 | 2023 | Board Observer |
Max DeNies | - | 2023 | Board Observer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review